New oral drug shows promise against deadly lassa fever in west africa trial

NCT ID NCT07419373

Ongoing Disease control Sponsor: Arisan Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is to see if the new pill is safe and can reduce the virus faster than the current treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LASSA FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Communicable Diseases, Emerging Lassa fever Neglected Diseases viral hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LASSA FEVER

Contacts and locations

Show contact details

Locations

Abubakar Tafawa Balewa University Teaching Hospital

Bauchi, Nigeria
Arisan Therapeutics

Carlsbad, California, 92008, United States
Federal Medical Centre, Owo

Owo, Ondo State, Nigeria
Irrua Specialist Teaching Hospital

Irrua, 310115, Nigeria